Global KRAS Inhibitors Market & Clinical Trials Forecast Report to 2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global KRAS Inhibitors Market & Clinical Trials Forecast 2028” report has been added to ResearchAndMarkets.com’s offering.

The advancement in clinical research has led to the identification of several oncogenes that are generally mutated in cancers. Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most frequently mutated oncogene in lung carcinomas, accounting for 25% of total incidence, half of which are KRASG12C mutations. Therefore, suitable research and development activities were carried out by pharmaceutical companies to develop novel KRAS inhibitors. To date, Lumakras developed by Amgen is the only KRAS inhibitor that has been approved for the management of non-small cell lung cancer.

Companies Mentioned

• Amgen
• Boehringer Ingelheim
• Codiak Biosciences
• Cotinga Pharmaceuticals
• Eli Lilly
• Gilead
• Johnson & Johnson
• Merck
• Mirati Therapeutics
• Moderna
• Oblique Therapeutics
• Revolution Medicines
• Silenseed

The approval of Lumakras for the treatment of patients with advanced KRAS G12C mutated non-small cell lung cancer marks a milestone for cancer therapy. Apart from the small-molecule inhibitor approach, researchers are also utilizing several other novel mechanisms to directly target KRAS including vaccines, adoptive T cell therapy, PROTACs, and CRISPR/Cas9 are emerging. Amid these approaches, a few KRAS vaccines have entered the initial phase of clinical trials. ELI-002 developed by Elicio Therapeutics is a structurally novel AMP vaccine targeting KRAS-driven cancers. The company is currently enrolling patients in AMPLIFY-201, phase-I/II clinical trial of ELI-002 in patients with solid tumors, including colorectal cancer and pancreatic ductal adenocarcinoma.

Since the entry of Lumakras in the market, the drug has shown high adoption rates in the market with global sales of about US$ 90 Million in 2021. The encouraging response to the novel drug has propelled the further research and development activities in this segment. The pipeline of KRAS inhibitors is highly crowded and consists of several potential candidates including Adagrasib, JQ443, GDC-6036, BI 1823911, JNJ-74699157, MK-1084, and others. Among them, Adagrasib is one of the most advanced KRAS inhibitors in phase-III clinical trials while the others are mainly present in phase-I/II clinical trials.

Although KRAS G12C inhibitors offer an important new therapeutic option for a subset of patients with cancers, clinical trial experience suggests that fewer than half of patients respond and responses can be short-lived. To mitigate these challenges, ongoing clinical trials of KRAS inhibitors are largely focused on evaluating novel rational combinations based on positive preclinical results. For instance, Bridge BioPharma in collaboration with Amgen is evaluating the combination of BBP-398, SHP2 inhibitor in combination with Lumakras in patients with advanced solid tumors with the KRAS G12C mutations. In addition to this, Mirati Therapeutics also announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of adagrasib with Sanofi’s investigational SHP2 inhibitor SAR442720 (RMC-4630).

With advances in precision medicine, there is an unmet need for biomarker testing as it informs the treatment options during disease. For KRAS mutations, Qiagen 2021 announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RCQ PCR kit (therascreen KRAS Kit) after it received US regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with Lumakras. The company has collaborated with Labcorp to market the diagnostic test in the US.

As per report findings, it is estimated that the global KRAS inhibitor market will surpass US$ 4.5 Billion by 2028 driven by the growing demand for targeted therapies and high acceptance in cancer management. The report offers comprehensive insights into the pipeline therapeutics scenario and growth prospects across KRAS Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, commercial information of already available KRAS inhibitors, and sales forecast till 2028. The report also provides a regional analysis of the KRAS inhibitor market in the US, Europe, China, Japan, Canada, Brazil, and other promising regions.

The report highlights include:

• KRAS Inhibitors Market Opportunity: > USD 4.5 Billion by 2028
• US To Dominate Global KRAS Inhibitors Market: >50% Market Share
• Number of KRAS Inhibitors In Trials: > 45 Drugs
• Number of Approved Drugs: 1 (Lumakras)
• Lumakras Dosage, Sales, Patent & Price Insight
• Solid Tumors Targeted Drugs Dominating The Clinical Trials
• Global KRAS Inhibitors Market Trends & Dynamics
• Global KRAS Inhibitors Market Future Opportunity Outlook

Key Topics Covered:

1. Introduction to KRAS Inhibitors

2. KRAS Inhibitors – Mode of Action

3. Role of KRAS Inhibitors in Cancer Therapy

4. KRAS Inhibitors For Targeting Lung Cancer

5. KRAS Inhibitors in Pancreatic Cancer

6. KRAS Inhibitors for Colorectal Cancer

7. KRAS inhibitors For Other Cancers

8. Lumakras – 1st Approved KRAS Inhibitor

9. Global KRAS Inhibitor Market Overview

10. KRAS Inhibitor Market Regional Analysis – Based On Drug Approval

11. Global KRAS Inhibitors Clinical Trials Indicators

12. Global KRAS Inhibitors Clinical Pipeline By Company, Indication & Phase

13. Marketed KRAS Inhibitors Clinical Insight

14. Global KRAS Inhibitors Market Dynamics

14.1 Driving Factors for KRAS Inhibitor Market

14.2 Challenges for KRAS Inhibitors Market

15. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/wq8jpt

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900